Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Coherus BioSciences Inc. CHRS

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

The Power Play by The Market Herald
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Stock Price Chart (NDAQ:CHRS)

Fundamentals Snapshot (NDAQ:CHRS)

Current News (NDAQ:CHRS)

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

GlobeNewswire January 9, 2023

Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

GlobeNewswire December 25, 2022

Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

GlobeNewswire December 24, 2022

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

GlobeNewswire November 8, 2022

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

GlobeNewswire November 1, 2022

Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

GlobeNewswire October 12, 2022

Coherus to Launch CIMERLI(TM) (ranibizumab-eqrn) in the United States on October 3, 2022

GlobeNewswire September 19, 2022

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 12, 2022

Opinion & Analysis (NDAQ:CHRS)

No current opinion is available.

Bullboard Posts (NDAQ:CHRS)